KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities from Discontinued Operations: 2010-2025

Historic Liabilities from Discontinued Operations for TherapeuticsMD (TXMD) over the last 3 years, with Sep 2025 value amounting to $2.7 million.

  • TherapeuticsMD's Liabilities from Discontinued Operations fell 8.79% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 8.79%. This contributed to the annual value of $2.8 million for FY2024, which is 24.72% down from last year.
  • Per TherapeuticsMD's latest filing, its Liabilities from Discontinued Operations stood at $2.7 million for Q3 2025, which was down 2.02% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Liabilities from Discontinued Operations registered a high of $47.9 million during Q4 2021, and its lowest value of $1.4 million during Q2 2023.
  • Moreover, its 3-year median value for Liabilities from Discontinued Operations was $2.8 million (2025), whereas its average is $3.7 million.
  • Its Liabilities from Discontinued Operations has fluctuated over the past 5 years, first tumbled by 85.70% in 2023, then spiked by 337.61% in 2024.
  • TherapeuticsMD's Liabilities from Discontinued Operations (Quarterly) stood at $47.9 million in 2021, then tumbled by 46.09% to $25.8 million in 2022, then plummeted by 85.70% to $3.7 million in 2023, then fell by 24.72% to $2.8 million in 2024, then decreased by 8.79% to $2.7 million in 2025.
  • Its Liabilities from Discontinued Operations was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.8 million in Q1 2025.